The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Optometry
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Campaigns & Insights
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2026 / November / Lipid Control of Light Sensitivity
Research & Innovations Latest News

Lipid Control of Light Sensitivity

Researchers reveal how PIP2 tunes rod photoreceptor signaling

11/4/2026 2 min read

Share

  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Scorecard
  • Quiz
  • Poll

Clinical Scorecard: Lipid Control of Light Sensitivity

At a Glance

CategoryDetail
ConditionLaboratory study of PIP2 regulation of purified human CNGA1 channels, the principal subunit of rod photoreceptor CNG channels.
Key MechanismsPIP2 binds a pocket at the interface between neighboring CNGA1 subunits, involving the voltage-sensing, pore, and C-linker regions, and inhibits channel gating by preventing progression to the fully open state, reducing apparent sensitivity to cGMP.
Target PopulationNo patients were studied; the research examined purified human CNGA1 channels relevant to rod photoreceptors.
Care SettingLaboratory study using reconstituted channels, functional assays, single-channel recordings, cryo-electron microscopy, and mutational experiments.

Key Highlights

  • Increasing PIP2 concentrations progressively reduced CNGA1 activity and apparent sensitivity to cGMP.
  • At 200 µM cGMP, 0.2% PIP2 reduced channel open probability by around 40%; 1% PIP2 suppressed opening by more than 90%.
  • PIP2 did not alter unitary conductance, supporting an effect on channel gating rather than ion permeation.
  • Cryo-electron microscopy showed closed and intermediate states with PIP2, but no fully open state, even with saturating cGMP.
  • Mutations at Arg407 and especially Lys445 reduced or abolished PIP2-mediated inhibition.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          No patients were studied; experiments used purified human CNGA1 channels reconstituted in liposomes and lipid nanodiscs.

          No treatment was tested. The authors identify the PIP2-binding pocket as a potential allosteric drug target and describe compounds that mimic or oppose PIP2 binding as a future possibility.

          Clinical Best Practices

            Related Resources & Content

              This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

              Related Content

              Newsletters

              Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

              Newsletter Signup Image

              False

              Advertisement

              False

              Advertisement

              Explore More in Ophthalmology

              Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

              False

              Advertisement
              The Ophthalmologist
              Subscribe

              About

              • About Us
              • Work at Conexiant Europe
              • Terms and Conditions
              • Privacy Policy
              • Your Privacy Choices
              • Advertise With Us
              • Contact Us

              Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

              Affiliations:

              Specialties:

              Areas of Expertise:

              Contributions:

              Disclaimer

              The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: